SwRI awarded an HHS $8.3 million contract extension for continued development of cyanide antidote

SWRI's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

Chemistry & Chemical Engineering

For immediate release

San Antonio — March 25, 2014 —The U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) has awarded Southwest Research Institute (SwRI) an $8.3 million contract extension to continue development of a nasal-delivery, first-line treatment system to combat cyanide poisoning using an intranasal formulation of isoamyl nitrite.

The 28-month contract, a follow-on option to a contract begun in 2011, will include development of additional clinical supplies, regulatory filings and testing in two animal models to show safety and efficacy to support FDA approval.

“This antidote could potentially save many lives in an emergency situation by allowing individuals to quickly administer — even self-administer — a life saving dosage of the isoamyl nitrite intranasally,” said Dr. Joe McDonough, principal investigator and director of SwRI’s Microencapsulation and Nanomaterials Department. “This formulation, using a nasal delivery method, is relatively low-cost and can be quickly and easily administered in a crisis situation unlike the current method that must be delivered by a trained medical professional.”

Cyanide exposure can prove lethal if not treated quickly and effectively. Current antidotes require intravenous administration, which does not enable quick treatment of large numbers of victims, such as in a terrorist situation. A nasal formulation could potentially save lives by allowing for rapid treatment of large numbers of patients and administration of metered dosages.

In 2011, BARDA awarded SwRI a $4.4 million contract to develop a drug formulation and delivery system to treat cyanide exposure.

During the base period of SwRI’s contract, nasal delivery of isoamyl nitrite was shown to be surprisingly effective at treating and rapidly reversing otherwise lethal cyanide exposure during nonclinical testing, according to McDonough.

“This is just one more program in SwRI’s 10 year effort to develop antidotes against toxic industrial chemicals and chemical weapons,” said Dr. Michael MacNaughton, vice president of the Chemistry and Chemical Engineering Division. “SwRI has a long history of developing new technology to support the Government. The Institute is a leader in the drug development and delivery field and is working toward new medical countermeasures for chemical agents, including this cyanide antidote.”

News Source : SwRI awarded an HHS $8.3 million contract extension for continued development of cyanide antidote

Copy this html code to your website/blog to embed this press release.